Co-administration of succinylated gelatine with a 99mTc-bombesin analogue, effects on pharmacokinetics and tumor uptake

The bombesin analogue, [99mTc-GGC]-(Ornithine)3-BN(2 –14), 99mTc-BN-O, targeting gastrin releasing peptide receptors (GRPr) on the surface of tumors, was pre-clinically investigated as potential imaging agent for single photon emission computed tomography (SPECT). In addition, the improvement of its pharmacokinetic profile (PK) was investigated thro ugh the co-administration of a succinylated gelatin plasma expander (Gelofusine), aiming to reduce its kidney accumulation and enhance its tumor-to-normal tissue contrast ratios.

Source: Nuclear Medicine and Biology - July 19, 2016 Category: Nuclear Medicine Authors: Christos C. Liolios, Stavros Xanthopoulos, George Loudos, Alexandra D. Varvarigou, Gregory B. Sivolapenko Source Type: research